Verrica Pharmaceuticals Inc Dossier - Source-backed chat

Verrica Pharmaceuticals Inc

VRCANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.33

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.79Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $82.4M

Enterprise Value $71.2M

Shares Outstanding 17.2M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Verrica Pharmaceuticals is transitioning from a clinical-stage biotech to a commercial-stage dermatology leader, anchored by YCANTH (the first and only FDA-approved treatment for molluscum contagiosum). While the company continues to experience near-term operating losses and has a limited cash runway extending into Q1 2027, its commercial momentum is strong. Dispensed applicator units grew 51.3% year-over-year in Q1 2026, and the commercial launch in Japan by partner Torii Pharmaceutical represents a significant ex-U.S. expansion. Furthermore, the company's pipeline—including a global Phase 3 program in common warts and the development of VP-315 for basal cell carcinoma—provides substantial long-term upside that is not fully reflected in the current valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$15.54

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

YCANTH sales growth flattens due to reimbursement hurdles or intense competition from at-home treatments like berdazimer gel. The company is forced to raise capital through highly dilutive equity offerings due to its short cash runway. Clinical delays or safety signals emerge in the Phase 3 common warts program or the VP-315 oncology pipeline.

Base CaseCentral scenario

$14.1755%

YCANTH continues its steady commercial ramp in the U.S., supported by an expanded sales force of approximately 50 representatives. Torii Pharmaceutical successfully commercializes YCANTH in Japan, generating consistent milestone and supply revenues. The company secures additional non-dilutive or minimally dilutive financing to extend its cash runway through clinical readouts for common warts and VP-315.

Bull CaseUpside scenario

$20.0025%

YCANTH adoption accelerates rapidly in the U.S. and Japan, exceeding commercial expectations. The Phase 3 common warts program delivers positive top-line data, paving the way for a major label expansion into a market of 22 million U.S. patients. VP-315 demonstrates robust efficacy in Phase 3 trials for basal cell carcinoma, attracting a high-value global oncology partnership that non-dilutively funds operations.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage with YCANTH as the only FDA-approved, HCP-administered therapy for molluscum contagiosum.
Strong commercial momentum with over 100,000 YCANTH units dispensed since launch and 51.3% YoY growth in Q1 2026.
Strategic partnership with Torii Pharmaceutical, which fully funds the first $40 million of the global Phase 3 common warts program.
Promising oncology pipeline asset (VP-315) targeting basal cell carcinoma with observed abscopal-like systemic immune effects.

Key Investment Risks

Short cash runway with aggregate cash of $20.6 million as of March 31, 2026, expected to fund operations only into Q1 2027.
Risk of near-term equity dilution if the company cannot secure non-dilutive funding or strategic partnerships.
Commercial execution risk, including dependency on payer coverage, reimbursement dynamics, and sales force productivity.
Clinical and regulatory risks associated with ongoing Phase 3 trials for common warts and future trials for VP-315.

Thesis Invalidation Triggers

A severe slowdown in YCANTH prescription volume or net product revenue growth over consecutive quarters.
Failure to initiate or complete the Phase 3 common warts clinical trials on the projected timeline.
Inability to secure additional financing or strategic partnerships before the cash runway expires in Q1 2027.
Negative clinical data or safety concerns arising from the VP-315 basal cell carcinoma program.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.